Boulevard Bio Launches With $65M for Autoimmune Pipeline

Boulevard Bio emerged from stealth on August 12, 2026, with approximately $65M in aggregate financing from founding investor Deerfield Management and affiliates. The New York company is advancing a three-program pipeline of multi-specific antibodies aimed at B cell-driven autoimmune diseases, beginning with a Phase 1 candidate for IgA nephropathy.

The news matters because Boulevard Bio is not starting with a discovery-stage idea and a distant clinical promise. Its lead program, BLVD101, is already in a study of healthy volunteers, while its broader pipeline spans B cell modulation and immune-reset strategies. The scientific opportunity is substantial, but the company still has to convert early pharmacology into durable patient benefit.

What Happened

Boulevard Bio’s official launch announcement describes approximately $65M in aggregate financing through equity capital and convertible notes from Deerfield Management and affiliates. The company did not label the financing as a conventional seed or Series A round, disclose a valuation, or provide a prior-round chronology, so treating it as a single priced round would overstate what was disclosed.

The company was incubated inside Deerfield Discovery and Development, or 3DC, Deerfield’s internal therapeutics research and development engine. Its headquarters are at Cure, a Deerfield affiliate in New York City, placing the operating company, scientific infrastructure, and founding capital inside the same company-building ecosystem.

Boulevard Bio is led by CEO Mahesh Karande and CMO Neil Solomons, MD. Its scientific co-founders are Georg Schett, MD, a rheumatologist and immunologist known for work on B cell biology, and Frank Nestle, MD, a Deerfield partner and CEO of 3DC. Jonathan Barratt, PhD, FRCP, is the founding advisor, while Deerfield Managing Director Brian Chow, PhD, chairs the board.

Why BLVD101 Matters

BLVD101, formerly DFX-1092, is a dual BAFF/APRIL-targeting bispecific antibody being evaluated in an ongoing Phase 1 single-ascending-dose study in healthy volunteers. BAFF and APRIL are signals that support B cell and plasma-cell biology, making them relevant to the production of pathogenic IgA and the immune complexes associated with IgA nephropathy.

Boulevard Bio reported that interim pharmacokinetic and pharmacodynamic findings showed strong IgA suppression and supported a potential 12-week dosing interval. The company also said BLVD101 was generally well tolerated in the interim analysis. These are early, company-reported findings in healthy volunteers, not proof that BLVD101 improves outcomes in patients with IgA nephropathy.

That distinction is more than regulatory fine print. Quarterly dosing could matter in a chronic disease because convenience can affect whether a therapy fits into a patient’s life, but the dosing thesis only becomes valuable if later studies confirm safety, biological activity, and clinical benefit over time.

The Broader IgA Nephropathy Context

The target pathway has an evidence base beyond Boulevard Bio. A 2024 scientific review described how BAFF and APRIL contribute to B cell activation and the production of galactose-deficient IgA1 and related autoantibodies, central elements in the current model of IgA nephropathy biology.

A June 2026 systematic review of randomized trials found that APRIL-targeted and dual BAFF/APRIL approaches reduced short-to-medium-term proteinuria in adults with primary IgA nephropathy. The authors also cautioned that longer follow-up is needed to understand durability, immune safety, and kidney outcomes. That is where the competitive standard is moving: not merely changing a laboratory marker, but proving that an upstream immune intervention can preserve health over time.

For Boulevard Bio, this creates both validation and pressure. The biology is credible enough to attract serious clinical competition, while BLVD101’s proposed differentiation rests on the combination of dual-target activity and a potentially less burdensome dosing schedule.

A Pipeline Built Around Multiple Layers of B Cell Disease

BLVD201, formerly MTS-128, extends the strategy beyond cytokine blockade. The trispecific CD19/BCMA/CD3 T cell engager is designed to address antibody-producing cells and the cells that replenish them, with the goal of producing a deeper immune reset in severe B cell-driven autoimmune disease. It is currently in IND-enabling studies following an exclusive global license from METiS TechBio in June 2026.

BLVD301 is a bispecific antibody directed at an undisclosed target combination supported, according to the company, by established genetic evidence. Boulevard Bio nominated the program as a development candidate in June 2026. Together, the three programs give the company several ways to test a single strategic thesis: different B cell-driven diseases may require different combinations of target, modality, depth, and dosing.

That portfolio design also reduces the temptation to make one molecule carry the entire company story. BLVD101 provides the first clinical test, BLVD201 introduces an immune-reset approach, and BLVD301 keeps a next-generation program moving behind them. A broad pipeline is not the same as a de-risked one, but it gives management more than one route to create evidence.

What the $65M Signals

Deerfield’s involvement goes beyond a financing logo. Boulevard Bio was incubated inside 3DC, its lead candidate was developed there, and several company leaders and board members maintain direct ties to the Deerfield ecosystem. That concentration can shorten the path between scientific decision-making and capital allocation while making execution quality easier to judge because responsibility is not scattered across a loose syndicate.

The financing gives Boulevard Bio room to advance a clinical lead, an IND-enabling program, and a preclinical development candidate. The company has not disclosed a program-by-program use-of-proceeds plan, hiring target, commercial timeline, or valuation, so the most useful near-term milestones are scientific rather than promotional: continued BLVD101 data, progress toward clinical testing for BLVD201, and clearer disclosure around BLVD301.

Boulevard Bio is entering a field where target validation no longer guarantees company differentiation. Its case will depend on whether multi-specific design, development discipline, and dosing convenience combine into medicines that meaningfully change care. The launch assembled capital, biology, and leadership on one block. The next phase has to show whether the pipeline can move patients farther than the announcement did.